159 related articles for article (PubMed ID: 10586339)
1. A phase II study of cisplatin, ifosfamide and doxorubicin in operable primary, axial skeletal and metastatic osteosarcoma. European Osteosarcoma Intergroup (EOI).
Voûte PA; Souhami RL; Nooij M; Somers R; Cortés-Funes H; van der Eijken JW; Pringle J; Hogendoorn PC; Kirkpatrick A; Uscinska BM; van Glabbeke M; Machin D; Weeden S
Ann Oncol; 1999 Oct; 10(10):1211-8. PubMed ID: 10586339
[TBL] [Abstract][Full Text] [Related]
2. Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup.
Souhami RL; Craft AW; Van der Eijken JW; Nooij M; Spooner D; Bramwell VH; Wierzbicki R; Malcolm AJ; Kirkpatrick A; Uscinska BM; Van Glabbeke M; Machin D
Lancet; 1997 Sep; 350(9082):911-7. PubMed ID: 9314869
[TBL] [Abstract][Full Text] [Related]
3. Presurgical window of carboplatin and surgery and multidrug chemotherapy for the treatment of newly diagnosed metastatic or unresectable osteosarcoma: Pediatric Oncology Group Trial.
Ferguson WS; Harris MB; Goorin AM; Gebhardt MC; Link MP; Shochat SJ; Siegal GP; Devidas M; Grier HE
J Pediatr Hematol Oncol; 2001; 23(6):340-8. PubMed ID: 11563767
[TBL] [Abstract][Full Text] [Related]
4. Highly effective reduced toxicity dose-intensive pilot protocol for non-metastatic limb osteogenic sarcoma (SCOS 89).
Shkalim-Zemer V; Ash S; Toledano H; Kollender Y; Issakov J; Yaniv I; Cohen IJ
Cancer Chemother Pharmacol; 2015 Nov; 76(5):909-16. PubMed ID: 26365289
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant chemotherapy for osteosarcoma of the extremities with synchronous lung metastases: treatment with cisplatin, adriamycin and high dose of methotrexate and ifosfamide.
Bacci G; Briccoli A; Ferrari S; Saeter G; Donati D; Longhi A; Manfrini M; Bertoni F; Rimondini S; Monti C; Forni C
Oncol Rep; 2000; 7(2):339-46. PubMed ID: 10671683
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups.
Ferrari S; Smeland S; Mercuri M; Bertoni F; Longhi A; Ruggieri P; Alvegard TA; Picci P; Capanna R; Bernini G; Müller C; Tienghi A; Wiebe T; Comandone A; Böhling T; Del Prever AB; Brosjö O; Bacci G; Saeter G;
J Clin Oncol; 2005 Dec; 23(34):8845-52. PubMed ID: 16246977
[TBL] [Abstract][Full Text] [Related]
7. Combined pre-operative chemotherapy with intra-arterial cisplatin and continuous intravenous adriamycin for high grade osteosarcoma.
Rha SY; Chung HC; Gong SJ; Shim KY; Ahn JB; Yang WI; Shin KH; Yoo NC; Kim JH; Roh JK; Lee CI; Kim BS
Oncol Rep; 1999; 6(3):631-7. PubMed ID: 10203605
[TBL] [Abstract][Full Text] [Related]
8. Results of API-AI based regimen in osteosarcoma adult patients included in the French OS2006/Sarcome-09 study.
Piperno-Neumann S; Ray-Coquard I; Occean BV; Laurence V; Cupissol D; Perrin C; Penel N; Bompas E; Rios M; Le Cesne A; Italiano A; Anract P; de Pinieux G; Collard O; Bertucci F; Duffaud F; Le Deley MC; Delaye J; Brugieres L; Blay JY
Int J Cancer; 2020 Jan; 146(2):413-423. PubMed ID: 31246277
[TBL] [Abstract][Full Text] [Related]
9. A phase I/II study of doxorubicin, ifosfamide, etoposide and interval methotrexate in patients with poor prognosis osteosarcoma.
McTiernan A; Meyer T; Michelagnoli MP; Lewis I; Whelan JS
Pediatr Blood Cancer; 2006 Mar; 46(3):345-50. PubMed ID: 16206197
[TBL] [Abstract][Full Text] [Related]
10. A comparison of two short intensive adjuvant chemotherapy regimens in operable osteosarcoma of limbs in children and young adults: the first study of the European Osteosarcoma Intergroup.
Bramwell VH; Burgers M; Sneath R; Souhami R; van Oosterom AT; Voûte PA; Rouesse J; Spooner D; Craft AW; Somers R
J Clin Oncol; 1992 Oct; 10(10):1579-91. PubMed ID: 1403038
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant and adjuvant chemotherapy with high-dose ifosfamide, doxorubicin, cisplatin and high-dose methotrexate in non-metastatic osteosarcoma of the extremities: a phase II trial in Japan.
Kudawara I; Aoki Y; Ueda T; Araki N; Naka N; Nakanishi H; Matsumine A; Ieguchi M; Mori S; Myoui A; Kuratsu S; Hashimoto N; Yoshikawa H
J Chemother; 2013 Feb; 25(1):41-8. PubMed ID: 23433444
[TBL] [Abstract][Full Text] [Related]
12. A phase II study of cisplatin, doxorubicin, and ifosfamide with peripheral blood stem cell support in patients with skeletal osteosarcoma and variant bone tumors with a poor prognosis.
Patel SR; Papadopolous N; Raymond AK; Donato M; Seong CM; Yasko AW; Lewis VO; Lin PP; Champlin R; Benjamin RS
Cancer; 2004 Jul; 101(1):156-63. PubMed ID: 15222001
[TBL] [Abstract][Full Text] [Related]
13. Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities. Results in 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin and doxorubicin.
Bacci G; Picci P; Ferrari S; Ruggieri P; Casadei R; Tienghi A; Brach del Prever A; Gherlinzoni F; Mercuri M; Monti C
Cancer; 1993 Dec; 72(11):3227-38. PubMed ID: 8242546
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant therapy of osteosarcoma--A Phase II trial: Southwest Oncology Group study 9139.
Zalupski MM; Rankin C; Ryan JR; Lucas DR; Muler J; Lanier KS; Budd GT; Biermann JS; Meyers FJ; Antman K
Cancer; 2004 Feb; 100(4):818-25. PubMed ID: 14770440
[TBL] [Abstract][Full Text] [Related]
15. Received dose and dose-intensity of chemotherapy and outcome in nonmetastatic extremity osteosarcoma. European Osteosarcoma Intergroup.
Lewis IJ; Weeden S; Machin D; Stark D; Craft AW
J Clin Oncol; 2000 Dec; 18(24):4028-37. PubMed ID: 11118463
[TBL] [Abstract][Full Text] [Related]
16. Results of methotrexate-etoposide-ifosfamide based regimen (M-EI) in osteosarcoma patients included in the French OS2006/sarcome-09 study.
Gaspar N; Occean BV; Pacquement H; Bompas E; Bouvier C; Brisse HJ; Castex MP; Cheurfa N; Corradini N; Delaye J; Entz-Werlé N; Gentet JC; Italiano A; Lervat C; Marec-Berard P; Mascard E; Redini F; Saumet L; Schmitt C; Tabone MD; Verite-Goulard C; Le Deley MC; Piperno-Neumann S; Brugieres L; ; ;
Eur J Cancer; 2018 Jan; 88():57-66. PubMed ID: 29190507
[TBL] [Abstract][Full Text] [Related]
17. Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup.
Lewis IJ; Nooij MA; Whelan J; Sydes MR; Grimer R; Hogendoorn PC; Memon MA; Weeden S; Uscinska BM; van Glabbeke M; Kirkpatrick A; Hauben EI; Craft AW; Taminiau AH; ;
J Natl Cancer Inst; 2007 Jan; 99(2):112-28. PubMed ID: 17227995
[TBL] [Abstract][Full Text] [Related]
18. A pilot study of short-course intensive multiagent chemotherapy in metastatic and axial skeletal osteosarcoma.
Janinis J; McTiernan A; Driver D; Mitchell C; Cassoni AM; Pringle J; Kilby A; Whelan JS;
Ann Oncol; 2002 Dec; 13(12):1935-44. PubMed ID: 12453863
[TBL] [Abstract][Full Text] [Related]
19. Doxorubicin and cisplatin with granulocyte colony-stimulating factor as adjuvant chemotherapy for osteosarcoma: phase II trial of the European Osteosarcoma Intergroup.
Ornadel D; Souhami RL; Whelan J; Nooy M; Ruiz de Elvira C; Pringle J; Lewis I; Steward WP; George R; Bridgewater J
J Clin Oncol; 1994 Sep; 12(9):1842-8. PubMed ID: 7521906
[TBL] [Abstract][Full Text] [Related]
20. Multimodal treatment with doxorubicin, cisplatin, and ifosfamide for the treatment of advanced or metastatic uterine leiomyosarcoma: a unicentric experience.
Hadoux J; Rey A; Duvillard P; Lhommé C; Balleyguier C; Haie-Meder C; Morice P; Tazi Y; Leary A; Larue C; Pautier P
Int J Gynecol Cancer; 2015 Feb; 25(2):296-302. PubMed ID: 25581897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
